The use of splenectomy to manage platelet transfusion refractoriness due to anti-human leukocyte antibodies in allogeneic stem cell transplantation
| Autor: | Rita Balter, Margherita Mauro, Pierluigi Piccoli, Simone Cesaro, Massimiliano De Bortoli, Anna Pegoraro, Francesco Saverio Camoglio |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_treatment
Splenectomy lcsh:Medicine Case Report Hematopoietic stem cell transplantation Pediatrics splenectomy 03 medical and health sciences 0302 clinical medicine immune system diseases allogeneic stem cell transplantation hemic and lymphatic diseases medicine alloimmunized patients biology business.industry anti-HLA transfusion refractoriness lcsh:R lcsh:RJ1-570 lcsh:Pediatrics Platelet transfusion refractoriness Transplantation Platelet transfusion surgical procedures operative 030220 oncology & carcinogenesis Immunology biology.protein Rituximab Stem cell Antibody business 030215 immunology medicine.drug |
| Zdroj: | Pediatric Reports, Vol 8, Iss 1 (2016) Pediatric Reports Volume 8 Issue 1 |
| ISSN: | 2036-7503 |
| Popis: | In patients undergoing hematopoietic stem cell transplantation (HSCT), refractoriness to platelet transfusion has been associated with graft failure, delayed engraftment, early mortality and decreased overall survival. Therapeutic strategies include plasma exchange, immunoglobulins, rituximab, and splenectomy. We describe here three patients with refractoriness to platelet transfusion due to anti-human leukocyte antibodies who were splenectomized before HSCT (two cases) and after HSCT (one case) due to the lack of efficacy of other therapies. Splenectomy was uneventful. All three patients achieved a full donor engraftment. We suggest that splenectomy is feasible and effective in HSCT patients to reduce the risk of graft failure or delayed engraftment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|